ONE-TWENTY TWO: Trading Financial Markets
Exploring the poetry in financial markets for students of money and economy since the year 2000.
(This is an excerpt from an article I originally published on Seeking Alpha on January 9, 2015. Click here to read the entire piece.) It is still very early in the new year, but I cannot help notice the relative strength exhibited by iShares Trust – iShares U.S. Home Construction ETF (ITB) and several major … Read more
(This is an excerpt from an article I originally published on Seeking Alpha on December 31, 2014. Click here to read the entire piece.) The concern for some solar investors going into December was that solar stocks were being unfairly sold off in sympathy with plunging oil prices. {snip} Source: FreeStockCharts.com In early December, I … Read more
As soon as I noticed the unusually high options trading activity in Conn’s Inc. (CONN), I triggered the trade I first discussed on December 12th. On the shortened trading day of Christmas Eve, January call options flew off the shelves in CONN. At the time of writing, the Jan $17.50s saw volume of 3,536 versus … Read more
$HLF catching my interest again as it rides into 50DMA resistance on heels of insider buying news. Shorts and put/call ratio at major highs — Dr. Duru (@DrDuru) November 26, 2014 Here are the follow-up details on this tweet from Wednesday, November 26th, 2014. Herbalife (HLF) has experienced a strong rally from recent lows. The … Read more
Intercept Pharmaceuticals, Inc. (ICPT) may indeed have the $5B blockbluster liver drug that RBC Capital Markets claimed in hiking its price target on the stock from $425 to $500. Gilead (GILD) may indeed buy out the company. Other analysts like Leerink Partners who raised its price target from $270 to $445, and Deutsche Bank who … Read more